{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.91","value":"-3.95"},{"groupId":"OG001","spread":"2.90","value":"-2.68"}]}],"title":"Change from baseline at lowest value"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.36","value":"-1.19"},{"groupId":"OG001","spread":"4.02","value":"-0.29"}]}],"title":"Change from baseline at last value"}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Because the PFS was longer for patients in the Afatinib arm than for patients in the chemotherapy arm, the period of data collection for ECOG status and body weight continued for a longer time in the Afatinib arm.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"MEAN","populationDescription":"RS. Only patients with baseline and at least one post-baseline assessment were included.","reportingStatus":"POSTED","timeFrame":"Baseline and throughout the trial until progression (every 3 weeks), up to 28 months.","title":"Change From Baseline in Body Weight","type":"SECONDARY","unitOfMeasure":"Kg."}